Date: 2016-11-09
Type of information: Nomination
Compound:
Company: Avrobio (USA - MA)
Therapeutic area: Cancer - Oncology - Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 9, 2016, Avrobio announced the expansion of its senior management with three key hires. Nerissa Kreher, MD, MS, MBA joins as Chief Medical Officer for Rare Diseases, Kathryn McNaughton, PhD joins as Senior Vice President of Portfolio and Program Management and Richard Pfeifer, PhD, DABT joins as Director of Preclinical Development.
- Dr. Kreher is a pediatric endocrinologist with deep academic, clinical research and biotechnology industry experience. She has held leadership roles in both clinical development and medical affairs within private start-up biotechnology and large biotechnology companies focused on rare diseases. Most recently Dr. Kreher was the Global Head of Clinical and Medical Affairs at Zafgen. Formerly she held roles of increasing responsibility at Shire, Alexion, Enobia Pharma, Genzyme and EMD Serono. Dr. Kreher received a BA from the University of North Carolina, an MD from East Carolina University School of Medicine, an MS in Clinical Research from Indiana University and an Executive MBA from Northeastern University.
- Dr. McNaughton has 20 years of experience in the biotech industry encompassing R&D, Program Management and assessment of business development opportunities. She brings to Avrobio deep expertise in global program leadership and orphan drug development, extending from the preclinical stage through commercialization. Dr. McNaughton was previously Vice President, R&D Pipeline Program Management at Synageva, and held roles of increasing responsibility at Shire and Praecis Pharmaceuticals. Dr. McNaughton earned a PhD in Chemistry from Princeton University and a BS in Chemistry from Monmouth University.
- Dr. Pfeifer is a board-certified toxicologist with substantial industry experience providing technical and strategic leadership in toxicology and drug safety assessment across a broad range of therapeutic areas. His expertise spans small-molecule pharmaceuticals, biopharmaceuticals, vaccines, medical devices and gene therapies. Dr. Pfeifer was previously Head of Toxicology at Shire, and held roles of increasing responsibility at Wyeth Research, Ciba-Geigy, and in the contract services industry. Dr. Pfeifer was also an Assistant Professor of Toxicology at Purdue University. Dr. Pfeifer pursued postdoctoral fellowships in Immunotoxicology at the Chemical Industry Institute of Toxicology and the National Institute of Environmental Health Sciences. He received a BS in Biology from Bucknell University and a PhD in Pharmacology from the University of Rochester School of Medicine & Dentistry.
Financial terms:
Latest news:
Is general: Yes
